Investment Thesis
Instil Bio exhibits critical fundamental weakness with zero revenue (100% YoY decline) and negative operating cash flow (-$1.3M) against only $5.0M in available cash, implying 3-4 quarters of runway. Despite a strong balance sheet with $110.7M equity and zero debt, the absence of commercialized products and accelerating cash burn poses existential risk to the clinical-stage biotech.
Strengths
- Strong balance sheet with $200.4M total assets and $110.7M stockholders equity
- No long-term debt; debt-to-equity ratio of 0.00x
- Improving net loss (-$4.2M) and EPS (-$0.62) trending positively YoY
Risks
- Zero revenue with 100% YoY decline; no apparent commercialized products
- Negative operating cash flow (-$1.3M) with critically low cash reserves ($5.0M)
- Insufficient cash runway (~3-4 quarters) to fund operations without capital raise or strategic event
- No insider buying activity in 90-day period suggests management confidence deficit
Key Metrics to Watch
- Cash position and burn rate; timeline to next financing event
- Clinical trial progress and regulatory pathway status
- Operating cash flow trend and path to revenue generation
Financial Metrics
Revenue
0.0
Net Income
-4.2M
EPS (Diluted)
$-0.62
Free Cash Flow
-1.3M
Total Assets
200.4M
Cash
5.0M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-3.8%
ROA
-2.1%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
39.87x
Quick Ratio
39.87x
Debt/Equity
0.00x
Debt/Assets
44.8%
Interest Coverage
-3.54x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T07:53:02.253137 |
Data as of: 2026-03-31 |
Powered by Claude AI